VIPR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL14447714	0.51	10/20
SCHEMBL4329513	0.78	9/20
SCHEMBL9437246	0.68	9/20
SCHEMBL15186057	0.59	9/20
SCHEMBL12993325	0.42	9/20
SCHEMBL4728191	0.65	8/20
SCHEMBL4728204	0.65	8/20
SCHEMBL8997961	0.56	8/20
SCHEMBL8997980	0.56	8/20
SCHEMBL15182358	0.70	7/20
SCHEMBL15235439	0.63	7/20
SCHEMBL16103867	0.53	7/20
SCHEMBL14447711	0.50	7/20
SCHEMBL8997940	0.62	6/20
SCHEMBL8997965	0.62	6/20
SCHEMBL8997988	0.62	6/20
SCHEMBL8998005	0.62	6/20
SCHEMBL15185947	0.53	6/20
SCHEMBL16055253	0.48	6/20
SCHEMBL16103872	0.47	6/20

Clinical trials — most relevant to VIPR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19	PHASE3	WITHDRAWN
Next Generation ORS: Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea	PHASE2/PHASE3	COMPLETED
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)	PHASE3	RECRUITING
Effects of Exenatide on Hypothalamic Obesity	PHASE1/PHASE2	COMPLETED
Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure	PHASE2	COMPLETED
Splanchnic Venous Capacitance in Postural Tachycardia Syndrome	PHASE2	RECRUITING
Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia	PHASE2	COMPLETED
Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment	PHASE1/PHASE2	RECRUITING
Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women	PHASE1	COMPLETED
Role of the Gut Sweet Taste Receptor in the Secretion of Glucagon-like Peptide-1 and Peptide YY	PHASE1	COMPLETED
The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients	nan	COMPLETED
Plastic Bronchitis and Protein Losing Enteropathy in Children With Single Ventricle Physiology	nan	COMPLETED
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache	nan	COMPLETED
Vasoactive Intestinal Peptide in COPD	nan	COMPLETED
NDPH Biomarker Study in Children and Adolescents	nan	COMPLETED
The Effect of Vasopressin on Glucose Regulation	nan	COMPLETED
Investigating Optimal Propionate Delivery to the Colon Using Stable Isotope Labeling	nan	COMPLETED
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment	nan	NOT_YET_RECRUITING
The Effect of PACAP27 on the Extra- and Intracerebral Arteries Assessed by Magnetic Resonance Angiography (MRA) on Healthy Volunteers	nan	COMPLETED
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD	nan	RECRUITING
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED
Gastrointestinal Hormonal Regulation of Obesity	nan	COMPLETED
QoL and Cognitive Function in Patients With Hypoparathyroidism	nan	COMPLETED
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load	nan	COMPLETED
RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis	nan	COMPLETED
A Study on the Effects of Combined FMT on Gut Microbiota and Eating Disorder Symptoms in AN	nan	NOT_YET_RECRUITING
Neuropeptides in the Humane Intra- og Extracerebral Circulation.	nan	COMPLETED
Effects of Intravenous [Pyr1]Apelin-13 on Healthy Volunteers With Artificially Induced SIAD	nan	COMPLETED
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a VIPR1 binder may also engage these)

Protein	Name	Similarity
Q28992	—	1.000	Q28992 →
P30083	—	1.000	P30083 →
P97751	—	1.000	P97751 →
O35659	—	1.000	O35659 →
O46502	—	0.999	O46502 →
VIPR2	Vasoactive intestinal polypeptide receptor 2	0.998	landscape →
Q5FWI2	—	0.998	Q5FWI2 →
P23811	—	0.998	P23811 →
GCGR	Glucagon receptor	0.995	landscape →
Q61606	—	0.995	Q61606 →
GLP1R	Glucagon-like peptide 1 receptor	0.995	landscape →
P32301	—	0.994	P32301 →
P34999	—	0.994	P34999 →
P41588	—	0.994	P41588 →
SCTR	Secretin receptor	0.994	landscape →
Q0P543	—	0.993	Q0P543 →
P43219	—	0.993	P43219 →
P35000	—	0.992	P35000 →
GIPR	Gastric inhibitory polypeptide receptor	0.991	landscape →
GHRHR	Growth hormone-releasing hormone receptor	0.991	landscape →
P43218	—	0.990	P43218 →
A0A2Z2U4G9	—	0.990	A0A2Z2U4G9 →
P32082	—	0.988	P32082 →
Q29627	—	0.987	Q29627 →
Q5IXF8	—	0.987	Q5IXF8 →
Q02644	—	0.987	Q02644 →
P30082	—	0.987	P30082 →
P70205	—	0.987	P70205 →
P49190	—	0.986	P49190 →
Q91085	—	0.986	Q91085 →